Pharmacogenetics of Psychotropic Drugs

di Lerer • 2002 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 10-15 giorni lavorativi

da €246,00 a € 233,70
accedi o registrati per vedere le promozioni a te riservate

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

Provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the findings that have already emerged. Coverage extends to antipsychotics, antidepressants, mood stabilizing, cognitive-enhancing and anxiolytic drugs. An essential reference for all clinicians and researchers working in this field.Table of Contents •. List of contributors. . Pt. I. Introduction. . 1. Genes and psychopharmacology: exploring the interface. 3. Pt. II. Clinical background and research design. . 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response. 21. 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology. 36. 4. Methodological issues in psychopharmacogenetics. 57. 5. Statistical approaches in psychopharmacogenetics. 72. Pt. III. Molecular background. . 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways. 95. 7. RNA processing regulation and interindividual variation. 127. Pt. IV. Pharmacokinetics. . 8. Pharmacogenetics of psychotropic drug metabolism. 157. 9. Pharmacogenetics of chiral psychotropic drugs. 181. Pt. V. Specific psychotropic drugs and disorders. . 10. Clozapine response and genetic variation in neurotransmitter receptor targets. 217. 11. Genetic factors underlying drug-induced tardive dyskinesia. 245. 12. Functional gene-linked polymorphic regions in pharmacogenetics. 267. 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders. 283. 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex. 300. 15. Genetic factors and long-term prophylaxis in bipolar disorder. 320. 16. Genetic influences on responsiveness to anticonvulsant drugs. 333. 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease. 360. 18. Genetic variation and drug dependence risk factors. 372. Pt. VI. Pharmacogenetics and brain imaging. . 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia. 391. Pt. VII. Industry perspectives. . 20. Pharmacogenetics in psychotropic drug discovery and development. 401. 21. High-throughput single nucleotide polymorphism genotyping. 420. . Index. 439